Clonal hematopoiesis with


Journal

Haematologica
ISSN: 1592-8721
Titre abrégé: Haematologica
Pays: Italy
ID NLM: 0417435

Informations de publication

Date de publication:
01 Dec 2023
Historique:
received: 21 02 2023
medline: 4 12 2023
pubmed: 29 6 2023
entrez: 29 6 2023
Statut: epublish

Résumé

Clonal hematopoiesis (CH) is an age-related condition driven by stem and progenitor cells harboring recurrent mutations linked to myeloid neoplasms. Currently, potential effects on hematopoiesis, stem cell function and regenerative potential under stress conditions are unknown. We performed targeted DNA sequencing of 457 hematopoietic stem cell grafts collected for autologous stem cell transplantation (ASCT) in myeloma patients and correlated our findings with high-dimensional longitudinal clinical and laboratory data (26,510 data points for blood cell counts/serum values in 25 days around transplantation). We detected CHrelated mutations in 152 patients (33.3%). Since many patients (n=54) harbored multiple CH mutations in one or more genes, we applied a non-negative matrix factorization (NMF) clustering algorithm to identify genes that are commonly co-mutated in an unbiased approach. Patients with CH were assigned to one of three clusters (C1-C3) and compared to patients without CH (C0) in a gene specific manner. To study the dynamics of blood cell regeneration following ASCT, we developed a time-dependent linear mixed effect model to validate differences in blood cell count trajectories amongst different clusters. The results demonstrated that C2, composed of patients with DNMT3A and PPM1D single and co-mutated CH, correlated with reduced stem cell yields and delayed platelet count recovery following ASCT. Also, the benefit of maintenance therapy was particularly strong in C2 patients. Taken together, these data indicate an impaired regenerative potential of hematopoietic stem cell grafts harboring CH with DNMT3A and PPM1D mutations.

Identifiants

pubmed: 37381752
doi: 10.3324/haematol.2023.282992
pmc: PMC10690900
doi:

Substances chimiques

PPM1D protein, human EC 3.1.3.16
Protein Phosphatase 2C EC 3.1.3.16

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

3308-3320

Subventions

Organisme : Wellcome Trust
Pays : United Kingdom

Références

Cancer Discov. 2022 Oct 5;12(10):2392-2413
pubmed: 35924979
Blood. 2018 Aug 9;132(6):587-597
pubmed: 29884741
Nat Genet. 2011 Dec 04;44(1):23-31
pubmed: 22138693
Nat Genet. 2020 Nov;52(11):1219-1226
pubmed: 33106634
Nat Commun. 2018 Jan 31;9(1):455
pubmed: 29386642
Science. 2017 Feb 24;355(6327):842-847
pubmed: 28104796
N Engl J Med. 2017 Jul 13;377(2):111-121
pubmed: 28636844
Clin Cancer Res. 2016 Dec 1;22(23):5783-5794
pubmed: 27235425
Leukemia. 2020 Dec;34(12):3256-3268
pubmed: 32203146
J Clin Oncol. 2017 May 10;35(14):1598-1605
pubmed: 28068180
N Engl J Med. 2014 Dec 25;371(26):2488-98
pubmed: 25426837
Cancer Discov. 2022 Jan;12(1):220-235
pubmed: 34429321
Blood. 2015 Jul 2;126(1):9-16
pubmed: 25931582
Adv Physiol Educ. 2010 Sep;34(3):128-33
pubmed: 20826766
Nat Genet. 2022 Oct;54(10):1514-1526
pubmed: 36138229
N Engl J Med. 2014 Dec 25;371(26):2477-87
pubmed: 25426838
Cell Stem Cell. 2017 Sep 7;21(3):374-382.e4
pubmed: 28803919
Br J Haematol. 2022 Oct;199(2):190-204
pubmed: 35796524
Nature. 2022 Jun;606(7913):335-342
pubmed: 35650444
Proc Natl Acad Sci U S A. 2004 Mar 23;101(12):4164-9
pubmed: 15016911
Leukemia. 2020 Aug;34(8):2198-2205
pubmed: 32457355
Genome Res. 2018 Nov;28(11):1747-1756
pubmed: 30341162
Lancet Oncol. 2019 Jan;20(1):57-73
pubmed: 30559051
J Clin Oncol. 2022 Sep 1;40(25):2889-2900
pubmed: 35377708
Proc Natl Acad Sci U S A. 1997 Jun 10;94(12):6048-53
pubmed: 9177166
J Clin Oncol. 2017 Oct 10;35(29):3279-3289
pubmed: 28742454
J Clin Oncol. 2017 Mar 20;35(9):963-967
pubmed: 28297630
Science. 2019 Nov 1;366(6465):
pubmed: 31672865
Am J Hematol. 2022 Dec;97(12):1538-1547
pubmed: 36087071
Am J Hematol. 2021 May 1;96(5):E157-E162
pubmed: 33580975
Nat Cancer. 2021 May;2(5):527-544
pubmed: 35122024
Leukemia. 2022 Dec;36(12):2912-2916
pubmed: 36274067
Blood. 2020 May 28;135(22):2000-2004
pubmed: 32181815
Cell Stem Cell. 2018 Feb 1;22(2):157-170
pubmed: 29395053
Blood. 2020 Oct 1;136(14):1590-1598
pubmed: 32746453
Br J Haematol. 2021 Feb;192(4):697-705
pubmed: 33616916
Cell Stem Cell. 2018 Nov 1;23(5):700-713.e6
pubmed: 30388424
Nat Commun. 2017 Aug 16;8(1):268
pubmed: 28814763
Blood. 2022 Oct 20;140(16):1753-1763
pubmed: 35512188
Nat Commun. 2020 Jun 12;11(1):2996
pubmed: 32533060
Blood. 2018 Sep 13;132(11):1095-1105
pubmed: 29954749
Cell Rep. 2018 Apr 3;23(1):1-10
pubmed: 29617651

Auteurs

Patrick Stelmach (P)

Department of Medicine V, Heidelberg University Hospital, Heidelberg, Germany; Division of Stem Cells and Cancer, German Cancer Research Center (DKFZ) and DKFZZMBH Alliance, Heidelberg, Germany; Heidelberg Institute for Stem Cell Technology and Experimental Medicine (HI-STEM, gGmbH), Heidelberg.

Sarah Richter (S)

Department of Medicine V, Heidelberg University Hospital, Heidelberg.

Sandra Sauer (S)

Department of Medicine V, Heidelberg University Hospital, Heidelberg.

Margarete A Fabre (MA)

Wellcome-MRC Cambridge Stem Cell Institute, University of Cambridge, Cambridge, UK; Department of Haematology, University of Cambridge, Cambridge, UK; Wellcome Sanger Institute, Wellcome Genome Campus, Cambridge, UK; Centre for Genomics Research, Discovery Sciences, BioPharmaceuticals R/D, AstraZeneca, Cambridge.

Muxin Gu (M)

Wellcome-MRC Cambridge Stem Cell Institute, University of Cambridge, Cambridge, UK; Department of Haematology, University of Cambridge, Cambridge, UK; Wellcome Sanger Institute, Wellcome Genome Campus, Cambridge.

Christian Rohde (C)

Department of Medicine V, Heidelberg University Hospital, Heidelberg.

Maike Janssen (M)

Department of Medicine V, Heidelberg University Hospital, Heidelberg.

Nora Liebers (N)

Department of Medicine V, Heidelberg University Hospital, Heidelberg, Germany; National Center for Tumor Diseases (NCT), Heidelberg.

Rumyana Proynova (R)

Department of Medicine V, Heidelberg University Hospital, Heidelberg.

Niels Weinhold (N)

Department of Medicine V, Heidelberg University Hospital, Heidelberg.

Marc S Raab (MS)

Department of Medicine V, Heidelberg University Hospital, Heidelberg.

Hartmut Goldschmidt (H)

Department of Medicine V, Heidelberg University Hospital, Heidelberg.

Birgit Besenbeck (B)

Department of Medicine V, Heidelberg University Hospital, Heidelberg.

Petra Pavel (P)

Stem Cell Laboratory, Institute of Clinical Transfusion Medicine and Cell Therapy Heidelberg GmbH, Heidelberg.

Sascha Laier (S)

Stem Cell Laboratory, Institute of Clinical Transfusion Medicine and Cell Therapy Heidelberg GmbH, Heidelberg.

Andreas Trumpp (A)

Division of Stem Cells and Cancer, German Cancer Research Center (DKFZ) and DKFZZMBH Alliance, Heidelberg, Germany; Heidelberg Institute for Stem Cell Technology and Experimental Medicine (HI-STEM, gGmbH), Heidelberg, Germany; Faculty of Biosciences, Heidelberg University, Heidelberg, Germany; German Cancer Consortium (DKTK), Heidelberg.

Sascha Dietrich (S)

Department of Medicine V, Heidelberg University Hospital, Heidelberg, Germany; Molecular Medicine Partnership Unit, European Molecular Biology Laboratory (EMBL), Heidelberg.

George S Vassiliou (GS)

Wellcome-MRC Cambridge Stem Cell Institute, University of Cambridge, Cambridge, UK; Department of Haematology, University of Cambridge, Cambridge, UK; Wellcome Sanger Institute, Wellcome Genome Campus, Cambridge.

Carsten Müller-Tidow (C)

Department of Medicine V, Heidelberg University Hospital, Heidelberg, Germany; National Center for Tumor Diseases (NCT), Heidelberg, Germany; Molecular Medicine Partnership Unit, European Molecular Biology Laboratory (EMBL), Heidelberg. carsten.mueller-tidow@med.uni-heidelberg.de.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH